<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326299</url>
  </required_header>
  <id_info>
    <org_study_id>BK92</org_study_id>
    <nct_id>NCT01326299</nct_id>
  </id_info>
  <brief_title>Post Prandial Glucose Control Proof-of-Principle</brief_title>
  <official_title>Post Prandial Glucose Control Proof-of-Principle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the postprandial glycemic response of subjects with
      type 2 diabetes when consuming a meal along with beverages containing various combinations of
      nutritional ingredients and fibers versus control beverage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive AUC from 0 to 240 minutes for plasma glucose.</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentrations</measure>
    <time_frame>0 to 240 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Nutritional ingredient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dissolve in water and consume with meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbohydrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dissolve in water and consume with meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#1 Nutrtitional ingredient + Fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dissolve in water and consume with meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#2 Nutritional ingredient + Fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dissolve in water and consume with meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>#3 Nutritional ingredient + Fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dissolve in water and consume with meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbohydrate placebo</intervention_name>
    <description>dissolve in water and consume with meal</description>
    <arm_group_label>Carbohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutritional ingredient</intervention_name>
    <description>Dissolve in water and consume with meals</description>
    <arm_group_label>Nutritional ingredient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>#1 Nutritional ingredient +Fiber</intervention_name>
    <description>Dissolve in water and consume with meal</description>
    <arm_group_label>#1 Nutrtitional ingredient + Fiber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>#2 Nutritional ingredient + Fiber</intervention_name>
    <description>Dissolve in water and consume with meal</description>
    <arm_group_label>#2 Nutritional ingredient + Fiber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>#3 Nutritional ingredient + Fiber</intervention_name>
    <description>Dissolve in water and consume with meal</description>
    <arm_group_label>#3 Nutritional ingredient + Fiber</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. type 2 diabetes

          2. between 21 and 75 years of age

          3. male or a non-pregnant, non-lactating female, at least 6 weeks postpartum or
             postmenopausal or surgically sterile

          4. BMI is &gt; 18.5 kg/m2 and &lt;35 kg/m2

          5. HbA1c &lt; 9.0%

        Exclusion Criteria:

          1. Subject uses exogenous insulin, exenatide, or sitagliptin phosphate

          2. type 1 diabetes.

          3. history of diabetic ketoacidosis.

          4. current infection

          5. active malignancy

          6. has had a significant cardiovascular event or history of congestive heart failure.

          7. end-stage organ failure or post organ transplant.

          8. history of renal disease.

          9. hepatic disease.

         10. history of gastrointestinal disorders

         11. chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or
             C, or HIV.

         12. taking any herbals, dietary supplements, or medications, other than oral hypoglycemic
             medications

         13. clotting or bleeding disorders.

         14. allergic or intolerant to any ingredient found in the study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Devitt-Maicher, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bobbie Swearengin, Director Clinical Research Operations</name_title>
    <organization>Abbott Nutrition</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

